Advances in the management of head and neck cancers – the new era of immunotherapies - Certificate of Completion
According to Cancer Australia, there were almost 5000 new cases of head and neck cancer diagnosed in Australia in 2017 making it the seventh most commonly diagnosed cancer in the country. More than 1000 Australians died from head and neck cancers during 2017, with a 5-year relative survival rate of 69% from 2009–2013. This has improved only marginally from 61% in 1984–1988.
SCCHN comprises a heterogeneous group of tumours that arise from the squamous epithelium of the oral cavity, oropharynx, larynx and hypopharynx. While many SCCHNs are related to behavioural risk factors such as smoking and alcohol use, infection with HPV (predominantly HPV-16 subtype) is associated with a clinically, genomically and immunologically distinct subgroup of tumours arising from the epithelium of the tonsil and base of the tongue. HPV-positive SCCHN is becoming increasingly common in many Western countries and is associated with improved prognosis compared with HPV-negative SCCHN.
This interactive online learning activity is valued at 1.5 Hour(s) of continuing education.
Associate Professor Alex Guminski
MBBS FRACP PhD
Medical Oncologist, Melanoma Institute Australia, Sydney
North Shore Private Hospital,
Royal North Shore Hospital, Sydney, NSW
Associate Professor Brett Hughes
BSc(Med) MBBS(Hons) FRACP
Senior Staff Specialist Medical Oncologist
Royal Brisbane and Women’s Hospital and
The Prince Charles Hospital Brisbane, QLD